BTIG raised the firm’s price target on Cryoport (CYRX) to $15 from $10 and keeps a Buy rating on the shares. The stock has been under some pressure over the past 2 years, but this is likely due to worries around the Inflation Reduction Act, tariffs, Most Favored Nation, and drug pricing reform risk, and the market appears to be turning the corner, the analyst tells investors in a research note. Cryoport’s gross margin and Product revenue growth are also showing good improvement, and the company has well over $400M of cash, the firm added.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYRX:
- CryoPort’s Promising Future: Buy Rating Backed by Strong Financials and Growing C> Market
- CryoPort Delays 10-Q Filing Due to Compilation Challenges
- Cryoport Inc’s Earnings Call Highlights Growth and Optimism
- CryoPort’s Strong Q2 2025 Performance and Growth Prospects Justify Buy Rating
- Disney reports Q3 beat and NFL deal, Uber authorizes $20B buyback: Morning Buzz